Container Performance Testing - New Proposal for USP General Chapter <671>

Recommendation
13-15 May 2025
Vienna, Austria
Practical Approaches for USP General Chapter <1058> Compliance in the QC Laboratory
In Pharmacopoeial Forum 39 (2) a proposal for the revision of USP General Chapter <671> was published. According to the summary of this change package integrity is necessary to maintain the drug product's quality throughout its shelf life. Packaging systems have to demonstrate satisfactory container-closure integrity. It is proposed that this chapter will be revised to include a new permeation method for determining barrier protection for packaging systems.
The purpose of this chapter is to provide standards for the functional properties of packaging systems used for solid oral dosage forms and liquid dosage forms for pharmaceuticals. Test methods are provided to measure moisture vapour transmission rates that are useful for pharmaceutical manufacturers to determine the level of barrier protection provided by packaging systems. Additional methods are provided to determine classification of packaging systems.
Definitions and moisture vapour transmission rates at 40°/75% relative humidity (RH)are given for the following blisters:
- Low-barrier blister - greater than 1.0 mg/cavity-day
- High-barrier blister - less than 1.0 mg/cavity-day
- Ultra-high barrier blister - less than 0.01 mg/cavity-day
Other methods may be used, if these alternative methods are described in sufficient detail to
justify their use.
More information can be found in the USP's Pharmacopeial Forum (PF).
Source: USP
Related GMP News
10.02.2025USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
10.02.2025FDA Warning Letter: Focus on Quality Control of APIs and Excipients
29.01.2025Revision of USP <1032> Design and Development of Biological Assays
23.01.2025English Translation of Supplement II to the Japanese Pharmacopoeia (JP18) Published
23.01.2025How to keep Analytical Systems Current and Compliant
23.01.2025FDA 483s due to Deficiencies in the Stability Program: Evaluation of Fiscal Year 2024